Stilla Technologies presents a novel approach for COVID-19 testing combining group testing with digital PCR and publishes the largest comparative study to date for group testing of SARS‐CoV‐2
The approach significantly reduces costs and increases testing capacity while offering a diagnostic sensitivity greater than the current standard of individual RT-PCR tests
Stilla Technologies, a leading French provider of pioneering solutions for high‐precision genetic analysis, is offering a new high-throughput and cost-effective testing approach for COVID-19 by combining its digital PCR technology with the group testing method and publishes the largest comparative study to date for group testing of SARS-CoV-2.
“We continue our efforts in the fight against Covid-19 and are proud today to present an innovative approach that greatly increases the testing capacity and meets the highest quality standards. This digital PCR based group testing method has a diagnostic sensitivity superior or equal to the current standard – that is individual RT-PCR testing – for group sizes up to 16 samples. The main benefit of this method is that it reduces the amount of reagent required to test a population by about 80% while reducing costs by as much and increasing test capacities by up to 10 times”, said Rémi Dangla, Co-founder and CEO of Stilla Technologies.